ACE-031
Also known as ACE-031 · ActRIIB-Fc · myostatin inhibitor decoy
New
Reconstitution & dosing guide
1 mg vial — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only1mg x 10 vials
ACE 031 · Not in current stock
$80 / vial
Prices per vial · Research use only · Not medical advice.
Soluble activin type IIB receptor fusion protein designed to trap myostatin/activin ligands and increase muscle mass; clinical development halted after safety signals.
How to picture it
Myostatin is a brake on muscle growth. ACE-031 acts like a decoy sponge for myostatin and related ligands — soaking up the brake signal so anabolic pathways face less resistance in research models. Picture releasing a natural speed limiter, not inventing a new growth hormone. High-interest and high-caution hypertrophy biology.
Research focus & benefits
- Myostatin decoy/ligand-trap research
- Muscle-limit pathway studies
- Anabolic brake-release model literature
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
ACE-031 is an ActRIIB-Fc decoy receptor that sequesters myostatin (GDF-8) and related TGF-β superfamily ligands. Early trials showed lean-mass increases but development stopped due to bleeding and vascular adverse events. Research interest continues in myostatin pathway biology.
Mechanism
Decoy ActRIIB extracellular domain fused to Fc binds GDF-8/activins, reducing SMAD2/3 inhibitory signaling on muscle growth.
Research uses
- Duchenne and muscle-wasting trial history
- Myostatin pathway pharmacology
- Lean-mass increase proof-of-concept studies
Research dosing notes
Clinical doses were carefully monitored. Research use is experimental and carries the class safety baggage that stopped development.
Half-life / kinetics
Days (Fc fusion PK)
Common research routes
Reported considerations
- Epistaxis and bleeding events in trials
- Vascular effects
- Unknown long-term safety
Contraindications / cautions
- Bleeding disorders
- Anticoagulant therapy
- Pregnancy
Common research stacks
- Follistatin-344
- IGF-1 LR3
- GDF-8 research materials
Legal / access note
Development discontinued clinically. Research material only; significant safety concerns.